Gilead's lenacapavir, a twice-yearly injectable for HIV prevention, is under FDA priority review. Clinical trials show 100% and 96% effectiveness, outperforming daily PrEP pills. If approved, it could boost adherence, reduce HIV cases, and improve global access. However, challenges include cost, long-term efficacy, and resistance risks. The FDA decision is expected by June 19, 2025.